- Home
- PFL vs RXST Comparison
PFL vs RXST Comparison
Compare PFL & RXST Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | PFL | RXST |
|---|---|---|
| Founded | 2003 | 1997 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Finance Companies | Biotechnology: Electromedical & Electrotherapeutic Apparatus |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 379.3M | 307.6M |
| IPO Year | 2003 | 2021 |
Fundamental Metrics
Financial Performance| Metric | PFL | RXST |
|---|---|---|
| Price | $8.27 | $7.51 |
| Analyst Decision | | Hold |
| Analyst Count | 0 | 11 |
| Target Price | N/A | ★ $11.50 |
| AVG Volume (30 Days) | 198.3K | ★ 710.0K |
| Earning Date | 01-01-0001 | 05-13-2026 |
| Dividend Yield | ★ 11.53% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $134,479,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $8.69 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $7.11 | $6.62 |
| 52 Week High | $8.70 | $27.13 |
Technical Indicators
Market Signals| Indicator | PFL | RXST |
|---|---|---|
| Relative Strength Index (RSI) | 41.24 | 37.97 |
| Support Level | $8.16 | $7.34 |
| Resistance Level | $8.49 | $9.11 |
| Average True Range (ATR) | 0.07 | 0.49 |
| MACD | -0.02 | -0.02 |
| Stochastic Oscillator | 47.69 | 18.86 |
Price Performance
Historical ComparisonAbout PFL PIMCO Income Strategy Fund Shares of Beneficial Interest
PIMCO Income Strategy Fund is a United States-based closed-end management investment company. The fund's investment objective is to seek high current income, consistent with the preservation of capital. The company seeks to achieve its objectives by investing in a diversified portfolio of floating and fixed-rate debt instruments.
About RXST RxSight Inc.
RxSight Inc is a commercial-stage medical technology company dedicated towards improving the vision of patients following cataract surgery. It offers intraocular lens technology that enables doctors to customize and optimize visual acuity for patients after cataract surgery. The company operates and manages its business in one reportable segment, the research and development, manufacture and sale of light adjustable lenses and related capital equipment.